COMPANY:

Natera

"Natera, Inc...today announced that the U.S. Food and Drug Administration (FDA) has approved Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq®) immunotherapy in MIBC."

P2/3 | "Based on the post-operative ctDNA status using personalized and tumor-informed assay (Signatera, bespoke assay), those who are ctDNA– (Cohort A) will be randomized to immediate AC with fluoropyrimidine (FP)+oxaliplatin (Ox) for 3-6 mos per established guidelines v serial ctDNA monitoring. Patients who are ctDNA+ post-operatively, or with serial monitoring (Cohort B), will be randomized to FP+Ox v more intensive AC with addition of irinotecan (I) for 6 mos...Dasari and Lieu contributed equally to the development of this trial. NCT05174169."

"Natera, Inc...today announced a publication in Clinical Cancer Research showing that Signatera was able to identify older women with early-stage ER+/HER2- breast cancer who can be managed with primary endocrine therapy (pET), without surgery." "

"Natera...today announced two peer-reviewed publications highlighting the clinical utility of Signatera, its personalized, tumor-informed circulating tumor DNA (ctDNA) assay, in anal squamous cell carcinoma (ASCC) and locally advanced rectal cancer (LARC)."

"Natera, Inc...today announced it will present new data in genitourinary malignancies at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 26-28, 2026."

P=N/A | "Study protocol adherence is high and no relevant study-related safety concerns have been identified to date.Conclusion ACES-EMB is the first randomized multicenter study to compare surveillance after HT with dd-cfDNA to EMB-based care. We anticipate the results of this study directly impact clinical care of heart transplant recipients and guidelines recommendations."

"Natera, Inc. (NASDAQ: NTRA)...today announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in JAMA Oncology. This publication builds on the initial presentation of results at the 2025 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI) earlier this year."

"Natera, Inc...together with Quantum Leap Healthcare Collaborative, today announced the publication of new findings from the I-SPY 2 trial in Nature Communications."

"Natera...together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Colorectal Cancer Study Group (ABCSG), today announced initial translational research results from the international randomized Phase III PALLAS study." "

"Natera...announced that new data on Signatera will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida. Natera and its collaborators will present four abstracts highlighting the clinical validity and utility of Signatera in hematologic malignancies."

"Natera, Inc...today announced that at least twelve abstracts highlighting Signatera will be shared at the 2025 San Antonio Breast Cancer Symposium (SABCS)"